ArticleslgStudy

chemistry

Zervimesine

Zervimesine is a chemistry topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Zervimesine rather than just read about it. In short: Zervimesine (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name CT-1812 or CT1812) is a sigma σ2 receptor antagonist which is under development for the treatment of Alzheimer's disease, dementia, dry age-related macular degeneration, and other indications. The drug shows high affinity for the sigma σ2 receptor (Ki = 8.5 nM).

Zervimesine — main illustration
Zervimesine — illustration

Key takeaways

  • Zervimesine belongs to chemistry; place it in that map before memorising details.
  • Learn the definition first, then one example that makes the definition concrete.
  • Connect Zervimesine to a quantity you can measure, compute or draw — that is where exam questions come from.
  • Reproduce the core statement of Zervimesine from memory before moving on to harder problems.

Reference excerpt

Zervimesine (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name CT-1812 or CT1812) is a sigma σ2 receptor antagonist which is under development for the treatment of Alzheimer's disease, dementia, dry age-related macular degeneration, and other indications. The drug shows high affinity for the sigma σ2 receptor (Ki = 8.5 nM). It also shows 7.4-fold lower affinity for the sigma σ1 receptor (Ki = 63 nM). Aside from the sigma σ1 receptor, the drug shows 100-fold selectivity for the sigma σ2 receptor over 72 other targets. The sigma σ2 receptor is a binding site for β-amyloid oligomers. Zervimesine has been found to diplace β-amyloid oligomers from the sigma σ2 receptor in both preclinical and clinical studies. As of 2024, effectiveness data on zervimesine for treatment of Alzheimer's disease are still lacking. Zervimesine is under development by Cognition Therapeutics. As of July 2025, it is in phase 2 clinical trials for Alzheimer's disease, dementia with Lewy bodies (DLB), and dry age-related macular degeneration. The drug was also being developed for treatment of other cognitive disorders, but development for this indication was discontinued.

See also List of investigational cognition and memory disorder drugs Blarcamesine

References

Worked examples

Example 1 — a first encounter with Zervimesine

Start with the simplest possible case. Write down what Zervimesine claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In chemistry, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Zervimesine before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Zervimesine ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Zervimesine

In research
Zervimesine appears in chemistry research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry
Engineering practice reuses Zervimesine in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom
Zervimesine is common in secondary-school and first-year university syllabi. It links to neighbouring topics Experimental drugs for Alzheimer's disease, Hydroxyarenes, Isobutyl compounds, so understanding it makes those chapters shorter.
In everyday life
Look for Zervimesine outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.
Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Zervimesine” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Zervimesine in 20 minutes

  1. Read the reference excerpt below once, without taking notes.
  2. Close the page and write down what Zervimesine means in your own words.
  3. Compare your version with the excerpt and mark what you missed.
  4. Work through the three examples above with pen and paper.
  5. Explain Zervimesine out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Zervimesine in simple terms?

Zervimesine (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code name CT-1812 or CT1812) is a sigma σ2 receptor antagonist which is under development for the treatment of Alzheimer's disease, dementia, dry age-related macular degeneration, and ot…

Why does Zervimesine matter?

Because it connects several chemistry ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Zervimesine?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Zervimesine.

Tags

  • Experimental drugs for Alzheimer's disease
  • Hydroxyarenes
  • Isobutyl compounds
  • Isoindoles
  • Mesyl compounds
  • Sigma antagonists

Keep exploring